Literature DB >> 29631361

Endocannabinoids in the Islets of Langerhans: the ugly, the bad, and the good facts.

Isabel González-Mariscal1, Josephine M Egan1.   

Abstract

The endocannabinoid system (ECS) regulates cellular homeostasis and whole-body metabolism. There is an autonomous ECS in the endocrine pancreas, including the cannabinoid 1 receptor (CB1R) that is present in β-cells. Here, we discuss conflicts that have arisen with regard to the function(s) of the ECs in the endocrine pancreas and that have caused confusion when defining the role of the ECS in islets of Langerhans, especially the role(s) of CB1R in β-cells. We also discuss the latest data published concerning the ECS in islets. CB1R in particular is not simply a negative modulator of insulin secretion as it is also involved in intra-islet inflammation during high fat-high sugar intake and it is a negative regulator of β-cell viability and turnover. We also discuss the feasibility of using CB1R as a target for the treatment of diabetes.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29631361      PMCID: PMC6139496          DOI: 10.1152/ajpendo.00338.2017

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  57 in total

1.  Evaluation of the insulin releasing and antihyperglycaemic activities of GPR55 lipid agonists using clonal beta-cells, isolated pancreatic islets and mice.

Authors:  A M McKillop; B M Moran; Y H A Abdel-Wahab; P R Flatt
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

2.  Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia.

Authors:  Isabel Matias; Marie-Paule Gonthier; Pierangelo Orlando; Vassilis Martiadis; Luciano De Petrocellis; Cristina Cervino; Stefania Petrosino; Laurence Hoareau; Franck Festy; Renato Pasquali; Regis Roche; Mario Maj; Uberto Pagotto; Palmiero Monteleone; Vincenzo Di Marzo
Journal:  J Clin Endocrinol Metab       Date:  2006-05-09       Impact factor: 5.958

3.  Cannabinoids induce pancreatic β-cell death by directly inhibiting insulin receptor activation.

Authors:  Wook Kim; Qizong Lao; Yu-Kyong Shin; Olga D Carlson; Eun Kyung Lee; Myriam Gorospe; Rohit N Kulkarni; Josephine M Egan
Journal:  Sci Signal       Date:  2012-03-20       Impact factor: 8.192

4.  Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

Authors:  Luc F Van Gaal; Aila M Rissanen; André J Scheen; Olivier Ziegler; Stephan Rössner
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

5.  Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing de novo synthesis of long-chain ceramides.

Authors:  Resat Cinar; Grzegorz Godlewski; Jie Liu; Joseph Tam; Tony Jourdan; Bani Mukhopadhyay; Judith Harvey-White; George Kunos
Journal:  Hepatology       Date:  2013-11-18       Impact factor: 17.425

6.  Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.

Authors:  André J Scheen; Nick Finer; Priscilla Hollander; Michael D Jensen; Luc F Van Gaal
Journal:  Lancet       Date:  2006-11-11       Impact factor: 79.321

7.  Identification and characterisation of a novel splice variant of the human CB1 receptor.

Authors:  Erik Ryberg; Huy Khang Vu; Niklas Larsson; Thierry Groblewski; Stephan Hjorth; Thomas Elebring; Sven Sjögren; Peter J Greasley
Journal:  FEBS Lett       Date:  2005-01-03       Impact factor: 4.124

8.  The cannabinoid CB1 receptor is expressed in pancreatic delta-cells.

Authors:  William G Tharp; Yong-Ho Lee; Rhonda L Maple; Richard E Pratley
Journal:  Biochem Biophys Res Commun       Date:  2008-05-27       Impact factor: 3.575

Review 9.  The phylogenetic distribution and evolutionary origins of endocannabinoid signalling.

Authors:  M R Elphick; M Egertová
Journal:  Handb Exp Pharmacol       Date:  2005

Review 10.  Endocannabinoid system as a regulator of tumor cell malignancy - biological pathways and clinical significance.

Authors:  Maria Pyszniak; Jacek Tabarkiewicz; Jarogniew J Łuszczki
Journal:  Onco Targets Ther       Date:  2016-07-18       Impact factor: 4.147

View more
  5 in total

1.  Anti-obesity therapy with peripheral CB1 blockers: from promise to safe(?) practice.

Authors:  Carmelo Quarta; Daniela Cota
Journal:  Int J Obes (Lond)       Date:  2020-04-21       Impact factor: 5.095

Review 2.  The Expanded Endocannabinoid System/Endocannabinoidome as a Potential Target for Treating Diabetes Mellitus.

Authors:  Alain Veilleux; Vincenzo Di Marzo; Cristoforo Silvestri
Journal:  Curr Diab Rep       Date:  2019-11-04       Impact factor: 4.810

Review 3.  Age-Related Changes in Glucose Metabolism, Hyperglycemia, and Cardiovascular Risk.

Authors:  Chee W Chia; Josephine M Egan; Luigi Ferrucci
Journal:  Circ Res       Date:  2018-09-14       Impact factor: 17.367

Review 4.  A Guide to Targeting the Endocannabinoid System in Drug Design.

Authors:  Adam Stasiulewicz; Katarzyna Znajdek; Monika Grudzień; Tomasz Pawiński; And Joanna I Sulkowska
Journal:  Int J Mol Sci       Date:  2020-04-16       Impact factor: 5.923

5.  Chronic marijuana usage by human pancreas donors is associated with impaired islet function.

Authors:  Meirigeng Qi; John S Kaddis; Kuan-Tsen Chen; Jeffrey Rawson; Keiko Omori; Zhen Bouman Chen; Sangeeta Dhawan; Jeffrey S Isenberg; Fouad Kandeel; Bart O Roep; Ismail H Al-Abdullah
Journal:  PLoS One       Date:  2021-10-27       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.